Anthropic’s prospective IPO could turn an obscure governance experiment into one of the market’s biggest tests of whether an AI company can put public benefit ahead of quarterly pressure. A listing that could value the Claude maker at as much as $2 trillion would bring a far broader—and potentially less patient—shareholder base into contact with its Long-Term Benefit Trust.¹

The trust was created to safeguard Anthropic’s goal of developing AI for humanity’s long-term benefit. It owns no equity, yet it can appoint or remove a majority of the board: four of the company’s seven directors. Its three current members—chair Neil Buddy Shah, former Federal Reserve chair Ben Bernanke and Center for a New American Security chief Richard Fontaine—receive advance warning of major actions, including model launches, and meet regularly with management.¹

So far, that influence has largely been advisory. Trustees encouraged a limited rollout of Anthropic’s Mythos cybersecurity model through the Glasswing Project and weighed in during the company’s dispute with the US government over automated weapons. But they have not yet imposed a defining trade-off between revenue and safety.¹

That unresolved moment is the crux of the IPO debate. Harvard Law School professor Jesse Fried calls the setup a “built-in conflict”: profit-seeking investors supply the capital, while self-appointed guardians decide how much profit may be sacrificed to advance the mission. “A deep and potentially unmanageable tension is thus hard-wired into the firms’ corporate DNA,” he wrote.¹

Anthropic’s supporters counter that investors entered with their eyes open and that safety was part of the investment case. One early backer nevertheless captured the commercial reality: “capitalism would win in the end.”¹ The trust also has a shareholder escape hatch—trustees can be removed with 85% of voting power—but an IPO may change who can wield it. Anthropic’s model now faces the stress test it was designed for.¹